I modelled Neuren's potential future guestimation of numbers over the weekend.
US $375K per patient
EU and Japan $150K (based on estimates that US pricing is on average 2.4x higher than these regions.
EU and Japan everything under $100K at 15% and over >$100K at 20% tiered royalties
To produce revenue estimate for NEU excluding Fragile X or NNZ2591
Assuming slower growth in EU and Japan (conservative keeping to lower end number of patients provided by Neuren)
Slowing of growth as some stop use and new patients pick up use.
Interested in feedback.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-112
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.96 |
Change
0.650(4.88%) |
Mkt cap ! $1.668B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $13.98 | $12.96 | $3.396M | 250.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 309 | $13.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.97 | 271 | 3 |
View Market Depth
| Last trade - 11.38am 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |